Laurence Legros
French Institute of Health and Medical Research
207 Papers
1K Citations
Laurence Legros is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Imatinib mesylate & Medicine. The author has an hindex of 38, co-authored 186 publications. Previous affiliations of Laurence Legros include Centre national de la recherche scientifique & University of Nice Sophia Antipolis.
Chat about Author
Papers
Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment‐free remission period after imatinib discontinuation: Results of the French Nilo post‐STIM study
Stéphanie Dulucq,Françoise Rigal-Huguet,Franck E. Nicolini,Pascale Cony-Makhoul,Martine Escoffre-Barbe,Martine Gardembas,Laurence Legros,Philippe Rousselot,Jixing Liu,Delphine Rea,Veronique De Mas,Sandrine Hayette,Sophie Raynaud,Fanny Robbesyn,Emilie Klein,Stephane Morisset,Francois-Xavier Mahon,Gabriel Etienne +17 more
TL;DR: In this paper , the efficacy and safety of nilotinib (300mg twice daily) in chronic myeloid leukaemia (CML) patients who experienced MRec, after imatinib discontinuation, was evaluated.
10
Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase.
Clémence Roux,Franck E. Nicolini,Delphine Réa,Mathilde Niault,Luigina Mollica,Françoise Berger,Catherine Chassagne-Clément,Isabelle Tigaud,Micheline Tulliez,Stéphane Giraudier,Ali Turhan,Philippe Rousselot,Laurence Legros +12 more
TL;DR: Dasatinib is a tyrosine kinase inhibitor licensed in the treatment of chronic myeloid leukemia known to exert immunomodulatory effects in vitro and in vivo.
10
Fluctuating Values of Molecular Residual Disease (MRD) without Molecular Progression After Imatinib Discontinuation in Patients (pts) with Chronic Myeloid Leukemia (CML) Who Have Maintained Complete Molecular Response: Implications for Re-Treatment Criteria and Role of Prior Interferon Therapy. A Pilot Study of the French CML Group (FILMC),
Philippe Rousselot,Pascale Cony Makhoul,Delphine Rea,Philippe Agape,Franck E. Nicolini,Laurence Legros,Michel Tulliez,Lydia Roy,Aude Charbonnier,Joelle Guilhot,François Guilhot,Francois-Xavier Mahon +11 more
TL;DR: Mahon et al. as discussed by the authors reported the results of imatinib discontinuation in CML pts in complete molecular response (CMR) for more than 2 years under IM therapy (STIM study).
10
Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/− Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone
Simone Boehrer,Odile Beyne-Rauzy,Thomas Prebet,Sophie Park,Agnès Guerci,Aspasia Stamatoulas,M.P. Chaury,Tony Jernival,Laurence Sanhes,Gérard Tertian,Stéphane Cheze,Eng-Mong Lim,Bachra Choufi,Denis Caillot,Eric Wattel,Jacques Delaunay,Laurence Legros,Fatiha Chermat,Françoise Isnard,Nathalie Cambier,Borhane Slama,Lydia Roy,Gandhi Damaj,Emmanuel Raffoux,François Dreyfus,Christian Recher,Norbert Vey,Sylvie Chevret,Pierre Fenaux,Claude Gardin +29 more
TL;DR: There was a trend for more frequent HI-E major after 6 courses in the AZA+EPO arm, according to the primary endpoint of the study, and IPSS cytogenetics was favorable in 73, intermediate in 18, adverse in 1 and failed in 1 cases, with no imbalance for all these characteristics between arms.
10
Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: a retrospective impact study
Michael Levraut,Laurence Legros,Charles Drappier,Marie C. Béné,Viviane Queyrel,Sophie Raynaud,Nihal Martis +6 more
TL;DR: Splenomegaly, however, is a statistically and clinically relevant indicator of a potential JAK2 mutation in patients with non-splanchnic thrombotic events and should require further assessment and a close follow-up.
10